Upcoming Webinars:
ASCPT Members-Only Webinar presented by Pharmacogenomics Community
Title: From a Genotype to Multiple Phenotypes: Drug-Induced and Disease-Induced Phenoconversion
Date and Time: Thursday, April 4, 2019, 11:00 am ET
Speakers: Jacques Turgeon, BPharm, PhD, and Veronique Michaud, BPharm, PhD
Moderators: D. Max Smith, PharmD
Description: In this presentation, examples of the heterogeneity observed in populations as it pertains to cytochrome P450 isoform activities (phenotype) will be reviewed. The presenters will dissect this variability by looking at the role of various variables such as individual characteristics such as age, gender, weight, disease, genotype and the role of environment. This webinar will address more specific phenoconversion situations (genotype/phenotype mismatches) due to concomitant drug administration. Finally, there will be a discussion on the influence of chronic inflammation on cytochrome P450 activities. Examples of misinterpretation of genotype results and unexpected drug response due to inappropriate dose use or drug selected will be presented. Tips will be provided on how to improve interpretation of genotype results to offer appropriate recommendations for drug use in patents with polypharmacy and various diseases.
Registration Link: https://attendee.gotowebinar.com/register/6140920173279774989
ASCPT Members-Only Webinar presented by the Early Development & Drug Safety and Systems Pharmacology Community
Title: Application of Quantitative Systems Toxicology in Drug Cardiovascular Safety Assessment
Date and Time: Tuesday, April 16, 2019, 12:00 pm ET
Speakers: Teresa Collins, Principal Scientist, and Sebastian Polak, PhD, Senior Principal Scientist
Moderators: Alice Ke, PhD, Senior Consultant and Scientific Advisor
Description: This webinar will describe the development of Quantitative Systems Toxicology & Safety (QSTS) as an approach to integrate relevant input data using bottom-up, top-down and middle out approaches. This will be exemplified through case studies involving cardiovascular safety/toxicity and conclude with a look at future challenges and opportunities. In this presentation, we will go beyond the well-documented drug-induced arrhythmia computational models such as the comprehensive in vitro proarrhythmia assay (CiPA) to address other potential cardiovascular safety risks.
Registration Link: https://attendee.gotowebinar.com/register/7936686543946230027